Paradoxes of non-trivial gene networks: How cancer-causing mutations can appear to be cancer-protective

Rejuvenation Research

Volumn 7, Issue 3, 2004, Pages 199-210

  Bains, William ^a,b  

^a Choracle Ltd   (United Kingdom)

^b Charade Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

AGING; ARTICLE; BAX GENE; CANCER; CANCER GENETICS; CANCER MODEL; DISEASE SEVERITY; GENE; GENE EXPRESSION; GENE MUTATION; GENE STRUCTURE; GENETIC MODEL; GENETIC SUSCEPTIBILITY; MDM 2 GENE; ONCOGENE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTECTION; RISK;

GENE EXPRESSION REGULATION; GENETIC MARKERS; HUMANS; MODELS, GENETIC; MUTATION; NEOPLASMS; ODDS RATIO; ONCOGENES; PROGNOSIS;

EID: 6344225680     PISSN: 15491684     EISSN: None     Source Type: Journal    
DOI: 10.1089/rej.2004.7.199     Document Type: Article

References (100)

1. Wright JC, Weinstein MC. Gains in life expectancy from medical interventions-standardizing data on outcomes. N Engl J Med 1998;339:380-386.
2. Weinstein MC. Gains in life expectancy from medical interventions, http://www.pophealth.wisc.edu/ wphi/education/seminars/weinstein.ppt (accessed May 4, 2004).
3. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-767.
4. Pollack JB. Connectionism: past, present and future. Artif Intell Rev 1989;3:3-22.
5. Bains W. Statistical mechanical prediction of non-Gomperzian ageing in extremely aged populations. Mech Ageing Dev 2000;112:89-97.
6. Bains W. Implications of the network structure of cellular control circuits for the design of anti-cancer vaccine therapies. Med Hypotheses 2002;58:403-410.
7. Anon. Proteomics in a small world. Nat Struct Biol 2002;9:153.
8. Ravdin PM, Chamness GC. The c-erbB-2 proto-oncogene as a prognostic marker and predictive parker in breast cancer: a paradigm for the development of other macromolecular markers-a review. Gene 1995;159:19-27.
9. Bowley R, Sanchez M. Introductory Statistical Mechanics. Oxford, UK: Clarendon Press, 1996.
10. Duesberg P, Rasnick D, Li R, et al. How aneuploidy may cause cancer and genetic instability. Ann Surg 1999;19:4887-4906.
11. Cox G, Jones JL, Andi A, et al. Bcl-2 is an independent prognostic factor and adds to a biological model for predicting outcome in operable non-small cell lung cancer. Lung Cancer 2001;34:417-426.
12. Natsugoe S, Matsumoto M, Okumura H, et al. Bax and BcI-X1 expression are not related to prognosis in patients with advanced esophageal squamous cell carcinoma. Cancer Lett 2001;174:91-97.
13. Hotz M, Bosq J, Zbaeren P, et al. Spontaneous apoptosis and expression of p53 and Bcl-2 family proteins in locally advanced head and neck cancer. Arch Otolaryngol Head Neck Surg 1999;125:417-422.
14. Granberg D, Wilander E, Öberg K, et al. Prognostic markers in patients with typical bronchial carcinoid tumours. J Clin Endocrinol Metab 2000;85:3425-3430.
15. Jäckel M, Sellmann L, Dorudian MA, et al. Prognostic significance of p53/bcl-2 co-expression in patients with squamous cell carcinoma. Laryngoscope 2000; 110:1339-1345.
16. Peiró G, Diebold J, Baretton GB, et al. Cellular apoptosis susceptibility gene expression in endometrial carcinoma: correlation with Bcl-2, Bax and Caspase-3 expression and outcome. Int J Gynaecol Pathol 2001;20:359-367.
17. Kurabayashi A, Furihata M, Matsumoto M, et al. Expression of Bax and apoptosis-related proteins in human esophageal squamous cell carcinoma including dysplasia. Mod Pathol 2001;14:741-747.
18. Garcia EJ, Lawson D, Cotsonis G, et al. Hepatocellular carcinoma and markers of apoptosis (bcl-2, bax, bcl-x): prognostic significance. Appl Immunohistochem Mol Morphol 2002;10:210-217.
19. Dijkema IM, Struikmans H, Dullens HFJ, et al. Influence of p53 and bcl-2 on proliferative activity and treatment outcome in head and neck cancer patients. Oral Oncol 2000;36:54-60.
20. Gregore V, Ludovini V, Pistola L, et al. Relevance of p53, bcl-2 and Rb expression on resistance to cisplatin-based chemotherapy in advanced non-small-cell lung cancer. Lung Cancer 2003;39:41-48.
21. Grossi F, Loprevite M, Chiaramondia M, et al. Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small-cell lung cancers. Eur J Cancer 2003;39:1242-1250.
22. Mejía MDC, Navarro S, Pellín A, et al. Study of proliferation and apoptosis in neuroblastoma. Their relation with other prognostic factors. Arch Med Res 2002;33:466-472.
23. Nagler RM, Kerner H, Laufer D, et al. Squamous cell carcinoma of the tongue: the prevalence and prognostic roles of p53, bcl-2, c-erbB-2 and apoptotic rate to clinical and patrhological characteristics in a retrospective study. Cancer Lett 2002;186:137-150.
24. Saleh HA, Jackson H, Khatib G, et al. Correlation of bcl-2 oncoprotein immunohistochemical expression with proliferation index and histopathologic parameters in colorectal neoplasia. Pathol Oncol Res 1999; 5:273-279.
25. Schwandner O, Schiedeck THK, Bruch H-P, et al. p53 and Bcl-2 as significant predictors of recurrence and survival in rectal cancer. Eur J Cancer 2000;36:348-356.
26. Uchida T, Gao J-P, Wang C, et al. Clinical significance of p53, mdm2 and bcl-2 proteins in renal cell carcinoma. Urology 2002;59:615-620.
27. Jayasurya A, Dheen ST, Yap W-M, et al. Inducible nitric oxide synthase and bcl-2 expression in nasopharangeal cancer: correlation with outcome of patients after radiotherapy. Int J Oncol Biol Physics 2003;56:837-845.
28. Ilyas M, Hao X-P, Wilkinson R, et al. Loss of bcl-2 expression correlates with tumour recurrence in colorectal cancer. Gut 1998;43:383-387.
29. Scherr DS, Vaughan EDJ, Wei J, et al. bcl-2 and p53 expression in clinically localised prostate cancer predicts response to external beam radiotherapy. J Urol 1999;162:12-16.
30. Mariani A, Sebo TJ, Katzmann JA, et al. Pretreatment assessment of prognostic indicators in endometrial cancer. Am J Obstet Gynecol 2000;182:1535-1544.
31. Pich A, Margaria E, Chiusa L. Oncogenes and male breast carcinoma: c-erB-2 and p53 coexpression predicts a poor survival. J Clin Oncol 2000;18: 2948-2956.
32. Elkhuizen PHM, van Slooten H-J, Clahsen PC, et al. High local recurrence risk after breast-conserving therapy in node-negative premenopausal breast cancer patients is greatly reduced by one course of perioperative chemotherapy: a European Organization for Research and Treatment of Cancer breast cancer cooperative group study. J Clin Oncol 2000;18:1075-1083.
33. Hwang C-F, Su C-Y, Huang S-C, et al. Low expression levels of p27 correlate with loco-regional recurrence in nasopharyngeal carcinoma. Cancer Lett 2003;189:231-236.
34. Williams JA, Wang Z-R, Parrish RS, et al. Fluorescence in situ hybridization analysis of HER-2/neu, c-myc and p53 in endometrial cancer. Exp Mol Pathol 1999;67:135-143.
35. Field JK, Spandidos DA. The role of ras and myc oncogenes in human solid tumours and their relevance in diagnosis and prognosis. Anticancer Res 1990;10:1-22.
36. Erttmann R, Tafese T, Berthold F, et al. 10 years' neuroblastoma screening in Europe: preliminary results of a clinical and biological review from the Study Group for Evaluation of Neuroblastoma Screening in Europe (SENSE). Eur J Cancer 1998;34:1391-1397.
37. Eskelinen M, Haglund UH. Prognosis of human pancreatic adenocarcinomas: review of clinical and histopathological variables and possible uses of new molecular methods. Eur J Surg 1999;165:292-306.
38. Lipponen P. Expression of c-myc protein is related to cell proliferation and expression of growth factor receptors in transitional cell bladder cancer. J Pathol 1995;175:203-210.
39. Erisman MD, Litwin S, Keidan RD, et al. Noncorrelation of the expression of the c-myc oncogene in colorectal cancer with recurrence of disease of patient survival. Cancer Res 1988;48:1350-1355.
40. Hilgenfeld E, Padilla-Nash H, McNeil N, et al. Spectral karyotyping and fluorescence in situ hybridization detect novel chromosomal aberrations, a recurring involvement of chromosome 21 and amplification of the MYC oncogene in acute myeloid leukemia M2. Br J Haematol 2001;113:305-317.
41. Klijn JGM, Berns MJJ, Foekens JA. Prognostic factors and response to therapy in breast cancer. In: Fentiman IS, Taylor-Papadimitriou J, eds. Cancer Surveys. Vol. 18. Breast Cancer. New York: CSH Press, 1993:165-198.
42. Lee JC, Wang S-T, Chow N-H, et al. Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery. Eur J Cancer 2002;38: 1065-1071.
43. Yang X, Zhang Z, Jia C, et al. The relationship between expression of c-ras, c-erbB-2, nm23, and p53 gene products and development of trophoblastic tumor and their predictive significance for the malignant transformation of complete hydatidiform mole. Gynecol Oncol 2002;85:438-144.
44. Carr JA, Havstad S, Zarbo RJ, et al. The association of HER-2/neu amplification with breast cancer recurrence. Arch Surg 2000;135:1469-1474.
45. Rosenthal S, Depowski PL, Sheeban CE, et al. Comparison of Her-2/neu oncogene amplification detected by fluorescence in situ hybridization in lobular and ductal breast cancer. Appl Immunohistochem 2002;10:40-46.
46. Knoop AS, Bentzen SM, Nielsen MM, et al. Value of epidermal growth factor receptor, HER2, p53 and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. J Clin Oncol 2001;19:3376-3384.
47. Tanner M, Jarvinsen P, Isola J. Amplification of HER-2/neu and topoisomerase II alpha in primary and metastatic breast cancer. Cancer Res 2001;61:5345-5348.
48. Thorgensen VB, Sorensen BS, Poulsen SS, et al. A subclass of HER1 ligands are prognostic markers for survival in bladder cancer patients. Cancer Res 2001;61:6227-6233.
49. Yan J, Fang Y, Huang B-J, et al. Absence of evidence for HER2 amplification in nasopharangeal carcinoma. Cancer Genet 2002;132:116-119.
50. Shih H-C, Shiozawa T, Kato K, et al. Immunohistochemical expression of cyclins, cyclin-dependent kinases, tumor-supression gene products, Ki-67, and sex steroid receptors in endometrial carcinoma: positive staining for cyclin A as a poor prognostic indicator. Hum Pathol 2003;34:471-478.
51. de Vicente JC, Herrero-Zapatero A, Fresno MF, et al. Expression of cyclin D1 and Ki-67 in squamous cell carcinoma of the oral cavity: clinicopathological and prognostic significance. Oral Oncol 2002;38:301-308.
52. Hirai T, Hayashi K, Takumida M, et al. Reduced expression of p27 is correlated with progression in precancerous lesions of the larynx. Auris Nasus Larynx 2003;30:163-168.
53. Hui A-M, Shi Y-Z, Li X, et al. Proliferative marker Ki-67 in gallbladder carcinomas: high expression level predicts early recurrence after surgical resection. Cancer Lett 2002;176:191-198.
54. Rioux-Leclerrcq N, Turlin B, Bansard J-Y, et al. Value of immunohistochemical Ki-67 and p53 determinations as predictive factors of outcome in renal cell carcinoma. Urology 2000;55:501-505.
55. Rodel C, Grabenbauer GG, Rodel F, et al. Apoptosis, p53, bcl-2 and Ki-67 in invasive bladder carcinoma: possible predictors for response to radiochemotherapy and successful bladder preservation. Int J Oncol Biol Physics 2000;46:1213-1221.
56. Sengupta PS, McGown AT, Bajaj V, et al. p53 and related proteins in epithelial ovarian cancer. Eur J Cancer 2000;36:2317-2328.
57. Sittel C, Ruiz S, Volling P, et al. Prognostic significance of Ki-67 (MIB1), PCNA and p53 in cancer of the oropharynx and oral cavity. Oral Oncol 1999;35: 583-589.
58. Visapää H, Bui M, Huang Y, et al. Correlation of Ki-67 and Gelsolin expression to clinical outcome in renal clear cell carcinoma. Urology 2003;61:845-850.
59. Saito H, Tsujitani, Oka S, et al. The expression of murine double minute 2 is a favourable prognostic marker in esophageal squamous cell carcinoma without p53 protein accumulation. Ann Surg Oncol 2002;9:450-456.
60. Skomedal H, Kristensen GB, Lie AK, et al. Aberrant expression of the cell cycle associated proteins TP53, MDM2, p21, p27, cdk4, cyclin D1, RB and EGFR in cervical carcinomas. Gynecol Oncol 1999;73:223-228.
61. Stein JP, Grossfeld GD, Ginsberg DA, et al. Prognostic markers in bladder cancer: a contemporary review of the literature. J Urol 1998;160:645-659.
62. Gerdes B, Ramaswamy A, Ziegler A, et al. p16INK4a is a prognostic marker in resected ductal pancreatic cancer: an analysis of p16INK4a, p53, MDM2 and Rb. Ann Surg 2002;235:51-59.
63. Kovar H, Auinger A, Jug G, et al. Narrow spectrum of infrequent p53 mutations and absence of MDM2 amplification in Ewing tumours. Oncogene 1993;8: 2683-2690.
64. Huang L-W, Chou Y-Y, Chao S-L, et al. p53 and p21 expression in precancerous lesions and carcinomas of the uterine cervix: overexpression of p53 predicts poor disease outcome. Gynecol Oncol 2001;83:348-354.
65. Kaye PV, Radebold K, Isaacs S, et al. Expression of p53 and p21(waf1/cip1) in gastric carcinoma: lack of inter-relationship or correlation with prognosis. Eur J Surg Oncol 2000;26:39-43.
66. Konstantinidou AE, Korkolopoulou P, Vassilopoulos I, et al. Reduced retinoblastoma gene protein to Ki-67 ratio is an adverse prognostic indicator for ovarian adenocarcinoma patients. Gynecol Oncol 2003;88:369-378.
67. Van de Putte G, Holm R, Lie AK, et al. Expression of p27, p21 and p16 protein in early squamous cervical cancer and its relation to prognosis. Gynecol Oncol 2003;89:140-147.
68. Lacoste-Collin L, Gomez-Brouchet A, Escourrou G, et al. Expression of p27(Kip1) in bladder cancers: immunohistochemical study and prognostic value in a series of 95 cases. Cancer Lett 2002;186:115-120.
69. Huang L-W, Chao S-L, Hwang J-L, et al. Down-regulation of p27 is associated with malignant transformation and aggressive phenotype of cervical neoplasms. Gynecol Oncol 2002;85:524-528.
70. Lacoste-Collin L, Gomez-Brouchet A, Escourrou G, et al. Expression of p27(Kip1) in bladder cancers: immunohistochemical study and prognostic value in a series of 95 cases. Cancer Lett 2002;186:115-120.
71. Vis A, Noordzij MA, Fitoz K, et al. Prognostic value of cell cycle proteins p27(Kip1) and MIB-1 and the cell adhesion protein CD44s in surgically treated patients with prostate cancer. J Urol 2000;164:2156-2161.
72. Hawes D, Liu PY, Muggia FM, et al. Correlation of p53 immunostaining in primary and residual ovarian cancer at the time of positive second-look laparotomy and its prognostic role: a Southwest Oncology Group ancillary study. Gynecol Oncol 2002;87:17-23.
73. Iniesta P, Vega FJ, Caldés T, et al. p53 exon 7 mutations as a predictor of poor prognosis in patients with colorectal cancer. Cancer Lett 1998;130:153-160.
74. Kawamura M, Ohnishi H, Guo S-X, et al. Alterations in p53, p21, p16, p15 and RAS genes in childhood T-cell acute lymphoblastic leukemia. Leuk Res 1999;23: 115-126.
75. Korkolopoulou P, Vassilopoulos I, Konstantinidou AE, et al. The combined evaluation of p27(Kip1) and Ki-67 expression provides independent information on overall survival of ovarian carcinoma patients. Gynecol Oncol 2002;85:404-414.
76. Kucera E, Speiser P, Gnant M, et al. Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor-positive breast cancer patients. Eur J Cancer 1999;5:398-105.
77. Nakayama K, Takebayashi Y, Nakayama S, et al. Prognostic value of overexpression of p53 in human ovarian carcinoma patients receiving cisplatin. Cancer Lett 2003;192:227-235.
78. Okuda T, Otsuka J, Sekizawa A, et al. p53 mutations and overexpression affect prognosis of ovarian endometrial cancer but not clear cell cancer. Gynecol Oncol 2003;88:318-325.
79. Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype and a poor prognosis. J Clin Oncol 2001;19:1405-1413.
80. Soulié P, Fourme E, Hamelin R, et al. TP53 status and gene amplification in human colorectal carcinomas. Cancer Genet Cytogenet 1999;115:118-122.
81. Straughn JMJ, Richter HE, Conner MG, et al. Predictors of outcome in small cell carcinoma of the cervix-a case series. Gynecol Oncol 2001;83:216-220.
82. Tralongo V, Rodolico V, Luciani A, et al, Prognostic factors in oral squamous cell carcinoma. A review of the literature. Anticancer Res 1999;19:3503-3510.
83. Jeng K-S, Sheen I-S, Chen B-F, et al. Is the p53 gene mutation of prognostic value in hepatocellular carcinoma after resection? Arch Surg 2000;135:1329-1333.
84. Shahin MS, Hughes JH, Sood AK, et al. The prognostic significance of p53 tumour suppressor gene alterations in ovarian carcinoma. Cancer 2000;98: 2006-2017.
85. Petersen S, Thames HD, Nieder C, et al. The results of colorectal cancer treatment by p53 status. Dis Colon Rectum 2001;44:322-334.
86. Borre M, Stausb l-Gr n B, Overgaard J. p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting. J Urol 2000;164:716-721.
87. Chen H-Y, Hsu C-T, Lin W-C, et al. Prognostic value of p53 expression in stage IB1 cervical carcinoma. Gynecol Obstet Invest 2000;49:266-271.
88. Ferrero J-M, Ramaioli A, Formento J-L, et al. p53 determination alongside classical prognostic factors in node-negative breast cancer: an evaluation at more than 10-year follow-up. Ann Oncol 2000;11:393-397.
89. Tammemagi MC, McLaughlin JR, Mullen JBM, et al. A study of smoking, p53 tumour supressor gene alterations and non-small-cell lung cancer. Ann Epidemiol 2000;10:176-185.
90. Ohsaki Y, Tanno S, Fujita Y, et al. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol Rep 2000;7:603-607.
91. Padua RA, Guinn B-A, Al-Sabah A, et al. RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year followup. Leukemia 1998; 12:887-892.
92. Lipponen P. Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. Int J Cancer 1993;53:365-370.
93. Ahnen DJ, Feigl P, Quan G, et al. Ki-ras mutation and p53 overexpression predict the clinical behaviour of colorectal cancer: a Southwest Oncology Group study. Cancer Res 1998;58:1149-1158.
94. Vähäkangas KH, Bennett WP, Castrén K, et al. p53 and K-ras mutations in lung cancers from former and never-smoking women. Cancer Res 2001;61: 4350-4356.
95. Niklinska W, Burzykowski T, Chzczewski L, et al. p53 gene mutation and protein expression in operable non-small-cell lung cance rin Poland. Eur J Cancer Prevent 2000;9:81-87.
96. Thongsuksai P, Bookyaphiphat P. Lack of association between p53 expression and betel nut chewing in oral cancers from Thailand. Oral Oncol 2001;37: 276-281.
97. Salvatore D, Celetti A, Fabien N, et al. Low frequency of p53 mutations in human thyroid tumours: p53 and Ras mutation in two out of fifty-six thyroid tumours. Eur J Endocrinol 1996;134:177-183.
98. Tsuchiya T, Sekine K-I, Hinohara S-I, et al. Analysis of the p16INK4, p14ARF, p15, TP53 and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma. Cancer Genet Cytogenet 2000;120:91-98.
99. Cordon-Cardo C, Wartinger D, Petrylak D, et al. Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J Natl Cancer Inst 1992;84:1251-1256.
100. Isaacs WB, Bova GB, Morton RA, et al. Molecular biology of prostate cancer progression. In: Olivegrun RTD, Wriglen PFM, eds. Cancer Surveys 23: Preventing Prostate Cancer: Screening vs. Chemoprevention. New York: CSH Press, 1995:19-32.